Clinical Trials
107 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
INDIGO
Boston Scientific Corporation
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Hoffmann-La Roche
Tumor HI
Rezolute
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
AbbVie
Project: Every Child for Younger Patients With Cancer
Children's Oncology Group
LIBRETTO-001
Eli Lilly and Company
DeLLphi-307
Amgen
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
Novo Nordisk A/S
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Vanderbilt-Ingram Cancer Center
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
DETERMINE
Cancer Research UK
REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)
Meyer Children's Hospital IRCCS
TENET
Tata Memorial Hospital
PharmTRT
Hospices Civils de Lyon
LIBRETTO-121
Eli Lilly and Company
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
TaiRx, Inc.
The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022
Suez Canal University
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor
Rezolute
Pan-MSI-ACSE
UNICANCER
ETP-NET
Hospices Civils de Lyon
DETERMINE
Cancer Research UK
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Children's Hospital of Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Circle Pharma
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Barbara Ann Karmanos Cancer Institute
LUTARTERIAL
University Hospital, Bordeaux
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Nuvation Bio Inc.
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
ARROW
Hoffmann-La Roche
LIFENETS
Sunnybrook Health Sciences Centre
SOLAR-1
Novartis
Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease
Tianjin Medical University
ECHO-NET
Istituto Clinico Humanitas
NET02
The Christie NHS Foundation Trust
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
ROOT
Taproot Health
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
EVACEL
Federation Francophone de Cancerologie Digestive
PitNET2024
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Hutchmed
BANN
University Medical Center Groningen
MONALEESA-3
Novartis
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
ALpha-T
Hoffmann-La Roche
NEM2A-Pheo
Assistance Publique Hopitaux De Marseille
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group